Biosimilars

June 18, 2020

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.

May 04, 2020

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

April 15, 2020

Merck has announced the US launch of trastuzumab-dttb (Ontruzant), a biosimilar to trastuzumab (Herceptin), in both 150-mg single-dose vials and 420-mg multiple-dose vials.

March 24, 2020

Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).

January 23, 2020

Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.

December 06, 2019

Biosimilar to Remicade

November 18, 2019

Expected U.S. launch in 2023.

October 01, 2019

Biosimilars may need more time to devleop in the market.

September 27, 2019

Biologic medicines could lower spending by $153 billion by 2023.

September 11, 2019

New changes are making it more difficult for generics and biosimilars to compete on formularies.